Efficacy of butylscopolamine for the treatment of catheter-related bladder discomfort: A prospective, randomized, placebo-controlled, double-blind study

British Journal of Anaesthesia

Volumn 111, Issue 6, 2013, Pages 932-937

  Ryu, J H ^a   Hwang, J W ^a   Lee, J W ^b   Seo, J H ^b   Park, H P ^b   Oh, A Y ^a   Jeon, Y T ^a   Do, S H ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Complications; Surgery; Urological

Indexed keywords

FENTANYL; GLYCOPYRRONIUM BROMIDE; MIDAZOLAM; NEOSTIGMINE; RAMOSETRON; ROCURONIUM; SCOPOLAMINE BUTYL BROMIDE;

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; BLADDER DISCOMFORT; BLURRED VISION; CATHETER COMPLICATION; CATHETER RELATED BLADDER DISCOMFORT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEPHROLITHOTOMY; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADICAL RETROPUBIC PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RECOVERY ROOM; SIDE EFFECT; SMOOTH MUSCLE CONTRACTION; TACHYCARDIA; URINARY CATHETER; UROLOGIC SURGERY; XEROSTOMIA;

EID: 84887930713     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet249     Document Type: Article

References (21)

1. Agarwal A, Raza M, Singhal V, et al. The efficacy of tolterodine for prevention of catheter-related bladder discomfort: A prospective, randomized, placebo-controlled, double-blind study. Anesth Analg 2005; 101: 1065-7.
2. Tauzin-Fin P, Sesay M, Svartz L, Krol-Houdek MC, Maurette P. Sublingual oxybutynin reduces postoperative pain related to indwelling bladder catheter after radical retropubic prostatectomy. Br J Anaesth 2007; 99: 572-5.
3. Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 1993; 45: 253-308.
4. Agarwal A, Dhiraaj S, Pawar S, Kapoor R, Gupta D, Singh PK. An evaluation of the efficacy of gabapentin for prevention of catheter- related bladder discomfort: A prospective, randomized, placebo-controlled, double-blind study. Anesth Analg 2007; 105: 1454-7.
5. Agarwal A, Dhiraaj S, Singhal V, Kapoor R, Tandon M. Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: A prospective, randomized, placebocontrolled, double-blind study. Br J Anaesth 2006; 96: 377-80.
6. Agarwal A, Gupta D, Kumar M, Dhiraaj S, Tandon M, Singh PK. Ketamine for treatment of catheter related bladder discomfort: A prospective, randomized, placebo controlled and double blind study. Br J Anaesth 2006; 96: 587-9.
7. Agarwal A, Yadav G, Gupta D, Singh PK, Singh U. Evaluation of intra-operative tramadol for prevention of catheter-related bladder discomfort: A prospective, randomized, double-blind study. Br J Anaesth 2008; 101: 506-10.
8. Tytgat GN. Hyoscine butylbromide: A review of its use in the treatment of abdominal cramping and pain. Drugs 2007; 67: 1343-57.
9. Chernik DA, Gillings D, Laine H, et al. Validity and reliability of the observer's assessment of alertness/sedation scale: study with intravenous midazolam. J Clin Psychopharmacol 1990; 10: 244-51.
10. Binhas M, Motamed C, Hawajri N, Yiou R, Marty J. Predictors of catheter-related bladder discomfort in the post-anaesthesia care unit. Ann Fr Anesth Reanim 2011; 30: 122-5.
11. Gupta D, Agarwal A, Dhiraaj S. Ketamine for treatment of catheterrelated bladder discomfort. Br J Anaesth 2005; 95: 720.
12. Greenstein A, Chen J, Matzkin H, Wassermann I, Braf Z. Transdermal scopolamine in prevention of post open prostatectomy bladder contractions. Urology 1992; 39: 215-8.
13. Patel PN, Ezzo DC. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: Treatment with meclizine. Am J Health Syst Pharm 2009; 66: 2024-6.
14. Andersson KE. Advances in the pharmacological control of the bladder. Exp Physiol 1999; 84: 195-213.
15. Carbone A, Palleschi G, Conte A, et al. Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol 2006; 29: 206-14.
16. Clemett D, Jarvis B. Tolterodine: A review of its use in the treatment of overactive bladder. Drugs Aging 2001; 18: 277-304.
17. Wefer J, Truss MC, Jonas U. Tolterodine: An overview. World J Urol 2001; 19: 312-8.
18. Igawa Y. Discussion: functional role of M(1), M(2), and M(3) muscarinic receptors in overactive bladder. Urology 2000;55: 47-9.
19. Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol 2001; 19: 299-306.
20. Yarker YE, GoaKL, Fitton A. Oxybutynin. Areview of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6: 243-62.
21. Schafer E, Ewe K. [The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon]. Fortschr Med 1990; 108: 488-92.